In Reply: We agree with Drs Deal and Hollands that the FDA-directed labeling for enoxaparin dosing in dialysis patients undergoing percutaneous coronary intervention is vague. The FDA revised the content and format of prescription drug labeling in 2006 to make prescribing information clearer and more concise.1 Yet, although eptifibatide and enoxaparin are both predominantly renally cleared and both associated with increased bleeding complications in patients undergoing dialysis, the FDA-directed labeling of the 2 drugs is quite different.
Tsai TT, Nallamothu BK, Rumsfeld JS. Contraindicated Medication Use in Dialysis Patients—Reply. JAMA. 2010;303(15):1481-1482. doi:10.1001/jama.2010.444